Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Refractory and Relapsed AML Patients

NCT05388305 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT05388305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Refractory and Relapsed AML Patients
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
April 20, 2022
Completion date
May 30, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml